RxDoctor Payments Data

Joseph Campbell, MD

Cardiology · Irvington, NJNPI 1053351569

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $898 of the $1,046 with a category attached, or 85.8%. 12 manufacturers reported payments, led by Novartis at 49.7% of the total. Reporting peaked in 2020 at $274 and has fallen 73.2% since, to $73 in 2025. That places this record below the midpoint for cardiology clinicians in NJ, where the typical reported total is $1,485.

$1,046in general payments, 2019–2025

Across 53 payments — averaging $19.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$520
  • Biotronik Inc.$148
  • Boehringer Ingelheim$119
  • Heartflow, Inc.$61
  • Boston Scientific$45
  • Amgen$29
  • plus $124 from 6 others

What the payments were for

  • Food & beverage$89886%
  • Education$14814%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,046 in reported general payments places this provider in the 40th percentile of 31 cardiology providers in New Jersey.

See all cardiology providers in New Jersey

Medicare billing

Part B allowed, 2024
$187,338
Medicare patients
154
Services billed
1,850

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan26$37,865
EliquisApixaban26$26,272
Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine18$4,016
ClopidogrelClopidogrel Bisulfate44$720
Atorvastatin Calcium44$661
Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid12$422
Metoprolol Succinate27$414
Rosuvastatin Calcium13$326
Enalapril Maleate14$304
Carvedilol24$264
Amlodipine Besylate24$193
Warfarin Sodium14$133
Furosemide43$115
Lisinopril19$94
Metoprolol Tartrate16$89

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$520$37,86526 claims
PfizerEliquis$28$26,27226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 31 cardiology providers in New Jersey.

Other cardiology in Irvington

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →